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Preterm infants exposed to inflammation are at increased risk of white matter injury and/or cerebral palsy. To investigate the effect of chronic inflammation on the developing white matter, we administered low-dose lipopolysaccharide once a day from postnatal days 3 to 11, examined white matter changes at postnatal day 12, and monitored serum levels of insulin-like growth factor 1 and insulin-like factor binding protein-3. A single injection of lipopolysaccharide decreased the serum insulin-like growth factor 1 level but not the insulin-like factor binding protein-3 level. At postnatal day 12, quantification of immunohistochemical staining for axonal, myelin, and oligodendrocyte markers revealed impaired myelination in subcortical white matter. In addition, brain gray matter volume decreased and spleen and liver weight increased at postnatal day 12. These data suggest chronic subclinical inflammation hampers development of white and gray matter in early life, which may be associated with insulin-like growth factor 1 deficiency.
Keywords: white matter damage; inflammation; neonatal brain injury; insulin-like growth factor 1 E xperimental evidence suggests that intrauterine inflammation induced by the gram-negative bacterial cell wall component lipopolysaccharide is closely related to the development of perinatal brain injury, including white matter injury, [1] [2] [3] [4] similar to that seen in preterm human infants. [4] [5] [6] [7] Recently, similar white matter damage was also observed in both midgestation and near-term fetal sheep, 8 suggesting the injurious effects of lipopolysaccharide may contribute to damage throughout pregnancy and white matter injury may not only be limited to vulnerability of immature (O4þ/O1-) oligodendroglia. 9 Insulin-like growth factor 1 plays an important role in childhood growth and continues to have anabolic effects in adults. It is also a neurotrophic factor promoting cell proliferation and differentiation during normal brain development and maturation, and it exerts biological effects on many cells, including oligodendrocytes in the central nervous system. 10 In addition, poor growth of head circumference has been associated with low serum insulin-like growth factor 1 levels in preterm infants. 11 After hypoxia-ischemia in infant rats, insulin-like growth factor 1 expression increases in the brain 12 ; insulin-like growth factor 1 administration protects the immature white matter from injury after cerebral ischemia in nearterm fetal sheep. 10 Lipopolysaccharide administration in rats decreases circulating insulin-like growth factor 1 and its gene expression in the liver. 13, 14 However, the effect of lipopolysaccharide on insulin-like growth factor 1 in neonatal mice is not known. We investigated the effects of lipopolysaccharide on insulin-like growth factor 1 and insulin-like factor binding protein-3 serum expression in neonatal mice. Furthermore, using a model of repeated low-dose lipopolysaccharide administration, mimicking a clinic situation of subclinical chronic inflammation, we also examined the effect on white and gray matter development.
Materials and Methods

Animals
Time-mated pregnant C57BL/6 mice were purchased from the Charles River Laboratories (Sulzfeld, Germany) and they gave birth in the animal facility (Experimental Biomedicine, University of Gothenburg, Gothenburg, Sweden). Day of birth was counted as postnatal day 0. Mice were housed with a 12-hour light/dark cycle. Free access to a standard laboratory chow diet (B&K, Solna, Sweden) and drinking water was provided. All animal experimentation was approved by the Ethical Committee of Gothenburg (no 314/05 or 375/08).
Lipopolysaccharide Administration
Dose response study. At postnatal day 6, mice offspring of both sexes were injected intraperitoneally with lipopolysaccharide (Escherichia coli 055:B5; Sigma, Stockholm, Sweden) 0.1, 0.3, and 0.5 mg/kg, or saline. Mice were sacrificed at 6 hours after injection by decapitation. Blood was collected and serum levels of interleukin 6, insulin-like growth factor 1, and insulin-like factor binding protein-3 were analyzed. For the repeated lipopolysaccharide experiments, the dose of 0.3 mg/kg lipopolysaccharide was chosen based on the interleukin 6 results above and our previous studies that showed low mortality with this dose. 15 Mice were injected intraperitoneally once a day from postnatal day 3 to postnatal day 11 and pups were sacrificed at postnatal day 12 and brain, spleen, and liver were collected and weighed.
Analysis of Interleukin 6, Insulin-Like Growth Factor 1, and Insulin-Like Factor Binding Protein-3
Serum interleukin 6 levels were measured using a mouse interleukin 6 enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, Minnesota) according to the manufacturer's instructions. Dilution factor used for lipopolysaccharidetreated mice was 1:100. Samples from control animals were under detection limit when diluted 1:5. According to the manufacturer, the intra-assay coefficients of variation for the interleukin 6 assay were 7.0%, 3.9%, and 3.5% at concentrations of 30, 87, and 232 pg/mL, respectively, and the interassay coefficients of variation were 6.1%, 8.9%, and 7.6% at concentrations of 29, 8, and 238 pg/mL, respectively.
Serum insulin-like growth factor 1 levels were measured using an insulin-like factor binding protein-3-blocked radioimmunoassay with a large excess of insulin-like growth factor 2 for determination of insulin-like growth factor 1 (Mediagnost GmbH, Tü bingen, Germany) according to a method described previously, with some modification. 16, 17 The intraassay coefficients of variations for the insulin-like growth factor 1 assay were 11.1%, 7.2%, and 7.4% at concentrations of 36, 204, and 545 mg/L, respectively, and the interassay coefficients of variations at these concentrations were 13.5%, 8.8%, and 9.9%. Serum insulin-like factor binding protein-3 levels were measured using a mouse insulin-like factor binding protein-3 enzyme-linked immunosorbent assay (R&D Systems) according to the manufacturer' instructions. The samples were diluted 1:500. The recovery of a spiked control was 90% in spiked serum sample and 94% in spiked control, diluted 1:500 to 1:4000. The linearity was within the range of 80% to 120% for dilutions 1:500 to 1:4000.
Immunohistochemical Staining
Pups at postnatal day 12 were deeply anesthetized and perfused intracardially with saline and 5% buffered formaldehyde (Histofix; Histolab, Göteborg, Sweden). Brains were removed and fixed in 5% buffered formaldehyde for 24 hours. After dehydration with graded ethanol and xylene, brains were paraffin-embedded and cut into 9-mm frontal sections. Parallel sections were used for various stains, as previously described. 18 Briefly, nonspecific binding was blocked for 30 minutes with 4% horse serum in phosphate-buffered saline. The following primary antibodies were used: microtubuleassociated protein-2 (MAP-2; clone HM-2, Sigma), rabbit antimyelin basic protein (Sternberger Monoclonal Incorporated, SMI 94, Lutherville, Massachusetts), anti-2 0 ,3 0 -cyclic nucleotide 3 0 -phosphodiesterase (MS-349-P; Lab Vision, Fremont, California), antiphosphorylated neurofilament (SMI 312; Sternberger Monoclonals), and oligodendrocyte lineage transcription factor 2 (AB15328, Chemicon International, Inc, Temecula, California). After incubating the primary antibodies for 60 minutes at room temperature, the appropriate biotinylated secondary antibodies (all from Vector, Burlingame, California) were applied for 60 minutes at room temperature. Visualization was performed using Vectastain ABC Elite with 0.5 mg/mL 3 0 -diaminobenzidine enhanced with 15 mg/mL ammonium nickel sulfate, 2 mg/mL b-D-glucose, 0.4 mg/mL ammonium chloride, and 0.01 mg/mL b-glucose oxidase (all from Sigma).
Gray Matter Volume and Subcortical White Matter Area Measurement
Gray matter area was determined by measuring the MAP-2 immunoreactive area and myelination was examined by measuring the subcortical white matter area stained for myelin basic protein, 2 0 ,3 0 -cyclic nucleotide 3 0 -phosphodiesterase, and neurofilament using Micro Image, version 4.0 (Micro-Macro AB, Gothenburg, Sweden) as previously described. 1, 8, 19 The volume of MAP-2-positive tissue was calculated according to the method described previously 20 using the following formula:
where V is the total volume, SA is the sum of the areas measured, p is the inverse of the section sampling fraction, and T is the section thickness. Oligodendrocyte lineage transcription factor 2-positive cell counting was performed using stereological principles (Stereo investigator 7, MicroBrightField System Inc, Magdeburg, Germany). Cells were counted at 8 levels in each brain with a counting frame of 75 Â 75 mm per section and the average number of positive cells/mm 2 was calculated. Results are presented as mean + standard error of the mean.
Statistics
Statistical programs StatView and Statistical Package for the Social Sciences (SPSS) were used. Analysis of variance followed by Fisher protected least significant difference post hoc test was used for comparing the interleukin 6 results with different doses of lipopolysaccharide. For all other analysis, Student unpaired t test was used to compare results between lipopolysaccharide and saline groups.
Results
Interleukin 6, Insulin-Like Growth Factor 1, and Insulin-Like Factor Binding Protein-3 Changes After Lipopolysaccharide Administration
There was no mortality at any of the lipopolysaccharide doses used. To confirm that lipopolysaccharide induced an appropriate inflammatory response, we measured the proinflammatory cytokine interleukin 6 at 3 different lipopolysaccharide doses: 0.1, 0.3, and 0.5 mg/kg. Interleukin 6 increased at 6 hours after lipopolysaccharide administration with all 3 doses ( Figure 1 ) and there were no significant differences between the different lipopolysaccharide doses. Therefore, on the basis of these results and our previous experiments, 15 a dosage of 0.3 mg/kg was chosen for all subsequent experiments.
To monitor changes in the insulin-like growth factor 1 system, serum levels of insulin-like growth factor 1 and insulin-like factor binding protein-3 were measured at 6 hours after administration of 0.3 mg/kg lipopolysaccharide to postnatal day 6 mouse pups. The lipopolysaccharide injection caused a significant decrease in insulin-like growth factor 1 serum levels at 6 hours after the injection (45% reduction; Figure 1 ). Insulin-like factor binding protein-3 serum levels were not altered at 6 hours after lipopolysaccharide in mice injected with 0.3 mg/kg lipopolysaccharide at postnatal day 6 ( Figure 1 ).
Brain, Liver, and Spleen Weight Changes After Lipopolysaccharide Administration
After administration of repeated lipopolysaccharide doses (0.3 mg/kg) once a day from postnatal day 3 to postnatal day 11, absolute brain weight (Figure 2 , panel A) and the relative brain weight to body weight (data not shown) were not different in lipopolysaccharide-exposed animals compared with saline-treated animals at postnatal day 12, and we found no infarctions, dilatation of the cerebral ventricles, or morphological signs of cell death after lipopolysaccharide administration. To examine the gray matter changes after repeated lipopolysaccharide treatment, brain gray matter volume was measured using immunohistochemical staining for the neuronal marker MAP-2. A significantly decreased gray matter volume was found in the lipopolysaccharide-treated mouse brain compared with saline-treated pup brains at postnatal day 12 (Figure 2, panel B) .
Moreover, there was a significant increase in both the absolute spleen and liver weights ( Figure 3) as well as the relative spleen-and-liver weight to body weight ratio (data not shown) at postnatal day 12 in animals repeatedly treated with lipopolysaccharide compared with those treated with saline; the difference was largest for the liver weight (Figure 3) .The whole body weight gain was not different between groups at postnatal day 12 (Figure 3 ).
White Matter Changes After Lipopolysaccharide Administration
To investigate the impact of repeated lipopolysaccharide administration on white matter, parallel sections from postnatal day 12 mouse brains were immunohistochemically stained with oligodendrocyte markers 2 0 ,3 0 -cyclic nucleotide 3 0 -phosphodiesterase and oligodendrocyte lineage transcription factor 2, myelin marker myelin basic protein, and axonal marker neurofilament. Quantification of the immunohistochemical staining for these markers demonstrated significantly decreased myelination, as indicated by reduced area of myelin basic protein and 2 0 ,3 0 -cyclic nucleotide 3 0 -phosphodiesterase staining in the subcortical white matter in lipopolysaccharidetreated animals compared with saline-treated animals (Figures 4 and 5) . Similarly, the number of cells positive for oligodendrocyte lineage transcription factor 2, a marker expressed both in early progenitors and at later stages in the oligodendrocyte lineage, 21 was significantly decreased in the lipopolysaccharide-treated animals compared with the saline-treated ones (Figure 4 ). Axons were visualized with neurofilament, one of the major cytoskeletal proteins of the axon. There were no significant differences in neurofilament immunohistochemical staining between the lipopolysaccharide-and saline-treated animals at postnatal day 12 (Figures 4 and 5 ).
Discussion
We found that repeated administration of a low dose of lipopolysaccharide from postnatal day 3 to postnatal day 11 impaired brain development, that is induced a decrease in the number of oligodendrocytes and reduced myelination of the white matter, as well as reduction in gray matter volume. Lipopolysaccharide was also found to decrease serum insulin-like growth factor 1 levels, which may suggest a role for this growth factor in the neuropathology observed.
In the rodent, there is a major growth spurt of the brain in the first postnatal week, 22 and the dominant cell type in the white matter is the preoligodendrocyte. 23, 24 This time period equates to the second-third trimester in human pregnancy, a window when white matter damage or deficiency of white matter growth is presumed to occur in the human. 9 This study used a repeated lipopolysaccharide exposure model from postnatal day 3 up to postnatal day 11, therefore, covering the period of rapid brain growth in rodents.
Lipopolysaccharide administered during pregnancy, either to the mother, directly to the fetus, or into the brain of newborn animals, caused white matter injury, indicated by reduced number of oligodendrocytes and/or hypomyelination. [1] [2] [3] [4] [25] [26] [27] [28] [29] The mechanisms behind this remain unclear and multiple factors have been suggested, such as hypoglycemia, 30, 31 hypoxemia, 3 selectively reduced white matter blood flow, 31 reduced cerebral oxygen delivery to the brain, 32 inflammation, 4,33,34 specific vulnerability of precursor oligodendrocytes, 35 excitotoxicity, and oxidative stress. 27, 36 In addition, recently published work suggests impaired development/deficiency of growth of both white and gray matter is common in preterm infants and actually more common than overt lesions. [37] [38] [39] [40] Similarly, in the current study, we observed hypomyelination in the subcortical white matter along with a decreased number of oligodendrocyte lineage transcription factor 2-positive cells, a marker for both precursor oligodendrocytes and mature oligodendrocytes, 21 suggesting impairment of white matter development either as a result of reduced proliferation/differentiation of oligodendrocytes or cellular loss. In contrast, axonal development, as shown by the quantification of neurofilament immunoreactivity, was not affected by repeated lipopolysaccharide treatment, agreeing with a previous study when lipopolysaccharide was administrated prenatally. 1 Taken together, these results suggest that inflammation affects oligodendroglia and myelin formation to a greater extent than the axons.
Insulin-like growth factor 1 signaling plays an important role in myelination, and a number of studies have shown that exogenous insulin-like growth factor 1 administration is beneficial. Insulin-like growth factor 1 was shown to prevent postischemic oligodendrocyte cell loss and associated demyelination and to stimulate proliferation, differentiation, and myelin production by oligodendrocytes in vitro. 41 In the neonate, insulin-like growth factor 1 provides neuroprotection to oligodendrocyte progenitor cells after cerebral hypoxia-ischemia. 42 In the current study, we found that a single intraperitoneal injection of low-dose lipopolysaccharide was sufficient to decrease insulin-like growth factor 1 serum levels. Similarly, lipopolysaccharide administration in adult rats induced a significant decrease in serum concentrations of insulin-like growth factor 1 and insulin-like factor binding protein-3 and body weight. 13, 43, 44 Given that insulin-like growth factor 1 has such a central role in the growth and development of the central nervous system, 45 it would be interesting to further investigate how diminished insulin-like growth factor 1 levels may contribute to lipopolysaccharide-induced impairment of gray and white matter development.
The brain weight and whole body weight did not differ between the lipopolysaccharide group and saline controls. This agrees with a previous study 46 in neonatal mice that shows that if lipopolysaccharide was given once at postnatal day 2, body weight and brain weight were not affected at postnatal days 5, 7, 14, and 28 but not with a study in rats. 47 The different effects on weight among various studies might reflect the different lipopolysaccharide dose used and the administration period. The liver and spleen play a central role in the systemic lipopolysaccharide response because the liver clears lipopolysaccharide from the circulation, and both liver and spleen release cytokines and reactive oxygen intermediates after lipopolysaccharide administration, which may reflect the liver and spleen weight increase observed in the current study.
In conclusion, chronic subclinical inflammation in early life inhibited white and gray matter development in neonatal mice. These cerebral changes were associated with reduced insulin-like growth factor 1 levels. Future studies will explore whether systemic inflammation impairs brain development through attenuation of insulin-like growth factor 1 tropic support.
